Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Baker Bros. Advisors Lp Insider Profile
102 Followers
Baker Bros. Advisors Lp, Ten Percent Owner at BioCryst, holds 10.00M shares in Bicycle Therapeutics (Ticker: BCYC), holds 9.01M shares in BeiGene (Ticker: BGNE), holds 2.76M shares in Kiniksa Pharmaceuticals (Ticker: KNSA).
Baker Bros. Advisors Lp BioCryst (BCRX)Ten Percent Owner
BioCryst (BCRX)
Ten Percent Owner
Ranked #189 out of 99,797 Corporate Insiders
Profitable Transactions
48 out of 87 Profitable Transactions
Average Return
+29.90%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Baker Bros. Advisors Lp's holdings
Insider Roles
Roles that Baker Bros. Advisors Lp holds in companies
Most Profitable Insider Trade
Stock:
Invitae
(NVTAQ)
(NVTAQ)
Rating:Informative Buy
Date:Mar 29, 2018 - Mar 29, 2019
Return:+399.30%
The most profitable trade made by Baker Bros. Advisors Lp
Baker Bros. Advisors Lp's Trading History
BioCryst
Aug 16, 2016
Ten Percent Owner
Informative Sell
20.25M
$114.03M
Bellicum Pharmaceuticals
Nov 24, 2023
―
Uninformative Buy
―
$160.49K
BeiGene
Dec 10, 2024
Director
Informative Sell
194.20M
$1.59B
Aceragen
Jul 03, 2019
―
Uninformative Buy
15.47K
$1.65M
Alexion Pharmaceuticals
May 18, 2020
―
Uninformative Buy
―
$1.47B
Kiniksa Pharmaceuticals
Oct 08, 2024
Director
Uninformative Buy
―
$56.83M
Hookipa Pharma
Apr 23, 2019
Former 10% owner
Informative Buy
12.50M
$1.66M
Kodiak Sciences
Jun 06, 2022
Director, Ten Percent Owner
Informative Buy
4.45M
$138.12M
IGM Biosciences
Oct 02, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$25.94M
Atreca
Oct 23, 2023
―
Informative Sell
109.90K
$267.40K
Zymeworks
―
Director
―
―
Prelude Therapeutics
Jan 29, 2021
Director, Ten Percent Owner
Uninformative Buy
133.33K
$12.03M
Spyre Therapeutics
―
Director
―
―
Talis Biomedical
Nov 19, 2021
Director, Ten Percent Owner
Informative Buy
218.00K
$13.17M
TScan Therapeutics
May 12, 2022
Director
Informative Buy
2.56M
$7.51M
Entrada Therapeutics Inc
Jun 06, 2022
Ten Percent Owner
Informative Buy
260.68K
$79.18M
DBV Technologies SA - American
Jun 13, 2022
Director, Ten Percent Owner
Uninformative Buy
―
$93.12M
Madrigal Pharmaceuticals
Jun 27, 2024
Director
Uninformative Buy
―
$553.60M
vTv Therapeutics
Mar 07, 2024
Director
Uninformative Sell
―
$1.34M
Kymera Therapeutics
Aug 22, 2024
Director
Informative Buy
46.41
$243.79M
Bicycle Therapeutics
Dec 17, 2024
Director, Ten Percent Owner
Uninformative Buy
21.23M
$146.73M
Immunocore Holdings
―
Director
―
―
Mirati Therapeutics
Nov 13, 2017
―
Informative Buy
2.20M
$2.13M
Neurogene
Oct 10, 2023
Director, Former 10% Owner
Uninformative Buy
―
$10.27M
Invitae
Mar 29, 2018
―
Informative Buy
5.00M
$83.09K
ACADIA Pharmaceuticals
May 31, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$667.30M
Xoma
Jul 23, 2015
Former 10% owner
Informative Sell
11.99M
$2.46M
Genomic Health
Oct 03, 2019
―
Uninformative Buy
124.47K
$484.81M
Incyte
Oct 02, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$1.98B
Seagen
Jun 02, 2023
―
Uninformative Buy
―
$9.84B
Synageva
―
―
―
―
List of latest transactions for each holding click on a transaction to see Baker Bros. Advisors Lp's performance on stock
You May Also Like
Baker Bros. Advisors Lp insider profile FAQ
What is the percentage of profitable transactions made by Baker Bros. Advisors Lp?
The percentage of profitable transactions made by Baker Bros. Advisors Lp is 55%.
What is the average return per transaction made by Baker Bros. Advisors Lp?
The average return per transaction made by Baker Bros. Advisors Lp is 29.90%.
What stocks does Baker Bros. Advisors Lp hold?
Baker Bros. Advisors Lp holds: BCRX, BLCM, BGNE, ACGN, ALXN, KNSA, HOOK, KOD, IGMS, BCEL, ZYME, PRLD, SYRE, TLIS, TCRX, TRDA, DBVT, MDGL, VTVT, KYMR, BCYC, IMCR, MRTX, NGNE, NVTAQ, ACAD, XOMA, GHDX, INCY, SGEN, GEVA stocks.
What was Baker Bros. Advisors Lp’s latest transaction?
Baker Bros. Advisors Lp latest transaction was an Uninformative Buy of $21.23M.
What was Baker Bros. Advisors Lp's most profitable transaction?
Baker Bros. Advisors Lp’s most profitable transaction was an Informative Buy of NVTAQ stock on March 29, 2018. The return on the trade was 399.30%.
What is Baker Bros. Advisors Lp's role in BioCryst?
Baker Bros. Advisors Lp's role in BioCryst is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.